Spectral domain optical coherence tomography in a patient with adult-onset vitelliform dystrophy treated with intravitreal bevacizumab.

Abstract

A patient with adult-onset vitelliform dystrophy received intravitreal injections of bevacizumab in one eye. During 4 months of follow-up, spectral domain optical coherence tomography (SD-OCT) showed a progressive decrease of yellowish deposits and complete resolution of subretinal fluid at the last followup. Despite the good anatomic outcome, the patient reported a mild decrease in visual acuity and persistent metamorphopsia. The clinical course and the correlation between the fundus findings and the morphologic information from SD-OCT data are described.

• Authors: Joo Yong Lee, Jongyoon Lim, Hyewon Chung, June-Gone Kim, Young Hee Yoon
• Journal: Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye (Ophthalmic Surg Lasers Imaging) 2009 May-Jun Vol. 40 Issue 3 Pg. 319-21 ISSN: 1542-8877 [Print] United States
• PMID: 19485301 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Fluorescein Angiography
• Follow-Up Studies
• Fourier Analysis
• Humans
• Injections
• Macular Degeneration (diagnosis, drug therapy)
• Male
• Middle Aged
• Tomography, Optical Coherence (methods)
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)
• Visual Acuity
• Vitreous Body